Hypothesis

Co‑delivery of a transiently expressed high‑fidelity Cas9 variant (HiFi‑Cas9) with the antioxidant N‑acetylcysteine (NAC) will significantly lower off‑target mutagenesis compared to standard Cas9, thereby permitting safe, repeated in vivo editing of longevity‑associated genes without triggering oncogenic transformation.

Rationale

• The analysis emphasizes that off‑target effects (OTEs) are the primary safety barrier for DIY CRISPR longevity attempts, with wild‑type Cas9 potentially editing up to 50 % of similar genomic sites [ Context].
• High‑fidelity Cas9 enzymes (e.g., SpCas9-HF1, eSpCas9) have been shown to reduce OTEs by >90 % in vitro while maintaining on‑target activity [Slaymaker et al., 2016].
• Reactive oxygen species (ROS) exacerbate Cas9‑induced DNA damage and impair DNA repair pathways, increasing the likelihood of mutagenic outcomes [Liu et al., 2020]. NAC, a precursor of glutathione, lowers intracellular ROS and enhances base excision repair (BER) and homologous recombination (HR) fidelity [Li et al., 2021].
• Combining HiFi‑Cas9 with NAC should therefore synergistically decrease both the generation of off‑target cuts and their misrepair, a mechanism not yet tested in aging models.

Experimental Design

1. Model: Ercc1‑/‑ progeroid mice (accelerated aging, median lifespan ~4‑5 months) [Wang et al., 2005].
2. Groups (n=15 per group):
   • Control: saline injection.
   • WT‑Cas9: AAV9 delivering SpCas9 + sgRNA targeting p16^Ink4a (senescence modulator) under a doxycycline‑inducible promoter.
   • HiFi‑Cas9: AAV9 delivering SpCas9-HF1 + same sgRNA.
   • HiFi‑Cas9 + NAC: Same as HiFi‑Cas9 group plus NAC administered in drinking water (2 g/L) throughout the experiment.
3. Induction: Doxycycline (2 mg/mL) for 5 days at 8 weeks of age to achieve transient Cas9 expression (peak ~48 h, cleared by day 7).
4. Readouts (at 3 months post‑induction):
   • Off‑target profiling: GUIDE‑seq or CIRCLE‑seq on liver, kidney, and spleen DNA; quantify unique off‑target sites >0.1 % allele frequency.
   • Genotoxicity: γH2AX foci, comet assay, and karyotype analysis.
   • On‑target efficacy: qPCR and Western blot for p16^Ink4a reduction.
   • Healthspan metrics: frailty index, grip strength, glucose tolerance, and histologic senescence (SA‑β‑gal) in tissues.
   • Lifespan: Kaplan‑Meier survival analysis.
5. Statistical Plan: Off‑target counts compared via Kruskal‑Wallis with Dunn’s post‑hoc; healthspan and lifespan analyzed by mixed‑effects models and log‑rank test (α = 0.05).

Expected Outcomes

• Primary: HiFi‑Cas9 + NAC group will show a ≥70 % reduction in detectable off‑target sites relative to WT‑Cas9 (p < 0.01) while maintaining ≥80 % on‑target p16^Ink4a knockdown.
• Secondary: Lower γH2AX foci and comet tail moments in HiFi‑Cas9 + NAC versus WT‑Cas9, indicating diminished DNA damage.
• Tertiary: Improved frailty scores, extended median lifespan (≥15 % increase over WT‑Cas9), and reduced senescence burden.

Falsifiability

If the HiFi‑Cas9 + NAC regimen does not produce a statistically significant reduction in off‑target events compared to WT‑Cas9, or if healthspan/lifespan improvements are absent despite efficient on‑target editing, the hypothesis is falsified. This would indicate that antioxidant co‑delivery does not sufficiently mitigate Cas9‑induced genomic instability in vivo, reinforcing the caution against unregulated longevity editing.